ArticleESMO open2026

Pembrolizumab plus chemotherapy as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma: 4.5-year follow-up from the randomized phase III KEYNOTE-859 study.

S Y Rha et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.